Authors
Zhihao Guo, Linyun Xiu, Yumei Li, Cailing Wei, Ji-Liang Li
Published in
International journal of biological macromolecules. Pages 154101. Aug 16, 2026. Epub Aug 16, 2026.
Abstract
Intravitreal chemotherapy is a widely employed therapeutic strategy for retinoblastoma. However, its clinical efficacy and safety are considerably compromised by rapid drug clearance from the vitreous cavity and off-target toxicity. To address these limitations, we developed a pH-responsive, hyaluronic acid-based dual drug-loaded nanoplatform (HDLNs) for intravitreal co-delivery of doxorubicin and lapatinib. The nanoscale dimensions and negative surface charge of HDLNs facilitate efficient diffusion within the vitreous gel network while enhancing cellular uptake by Y79 cells. Upon exposure to the acidic intracellular microenvironment, HDLNs rapidly disassemble and trigger the synchronized release of both payloads, thereby synergistically inhibiting tumor cell proliferation and migration. In vivo investigations demonstrated that intravitreal administration of HDLNs significantly prolonged intraocular drug retention and effectively suppressed tumor progression in an intraocular Y79 retinoblastoma mouse model. Importantly, HDLNs substantially mitigated ocular and systemic toxicities associated with intravitreal chemotherapy, exhibiting a favorable in vivo safety profile. Collectively, this tailored drug delivery nanoplatform represents a promising and feasible strategy for safe and effective intravitreal chemotherapy against retinoblastoma.
PMID:
42604682
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0